Terms: = Skin cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
94 results:
1. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
2. Intratumoral administration of the immunologic adjuvant AS01
Tijtgat J; Geeraerts X; Boisson A; Stevens L; Vounckx M; Dirven I; Schwarze JK; Raeymaeckers S; Forsyth R; Van Riet I; Tuyaerts S; Willard-Gallo K; Neyns B
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212127
[TBL] [Abstract] [Full Text] [Related]
3. Stereotactic radiosurgery of brain metastases: a retrospective study.
Gruber I; Weidner K; Treutwein M; Koelbl O
Radiat Oncol; 2023 Dec; 18(1):202. PubMed ID: 38115009
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract] [Full Text] [Related]
5. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
6. Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
Mehta I; Dayimu A; Kumar S; Boobier C; Oladipo O; Burke D; Olson-Brown A; Yesildag P; Nobes J; Brown S; Booth C; Wheater M; Muller D; Fountain V; Ford L; Board R; McGurk L; Twelves S; Demiris N; Corrie P
Eur J Cancer; 2023 Nov; 194():113344. PubMed ID: 37804771
[TBL] [Abstract] [Full Text] [Related]
7. Targeting Upregulated ciap2 in SOX10-Deficient Drug Tolerant Melanoma.
Glasheen MQ; Caksa S; Young AG; Wilski NA; Ott CA; Chervoneva I; Flaherty KT; Herlyn M; Xu X; Aplin AE; Capparelli C
Mol Cancer Ther; 2023 Sep; 22(9):1087-1099. PubMed ID: 37343247
[TBL] [Abstract] [Full Text] [Related]
8. Is an image-based eyelid management service safe and effective?
Gillam M; Younus O; Loo SP; Connolly J; Cauchi P; Gregory M; Drummond S; Chadha V
Eye (Lond); 2023 Dec; 37(17):3643-3647. PubMed ID: 37225825
[TBL] [Abstract] [Full Text] [Related]
9. Effect of selinexor on lipogenesis in virus-positive Merkel cell carcinoma cell lines.
Landes JR; Bartley BR; Moore SA; He Q; Simonette R; Rady PL; Doan HQ; Tyring SK
Clin Exp Dermatol; 2023 Jul; 48(8):903-908. PubMed ID: 37191210
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA MSC-AS1, as an oncogene in melanoma, promotes the proliferation and glutaminolysis by regulating the miR-330-3p/ YAP1 axis.
Tian T; Luo B; Shen G; Ji G
Anticancer Drugs; 2022 Nov; 33(10):1012-1023. PubMed ID: 36206100
[TBL] [Abstract] [Full Text] [Related]
11. treatment of Basal Cell Carcinoma with Electrochemotherapy: Insights from the InspECT Registry (2008-2019).
Bertino G; Muir T; Odili J; Groselj A; Marconato R; Curatolo P; Kis E; Lonkvist CK; Clover J; Quaglino P; Kunte C; Spina R; Seccia V; de Terlizzi F; Campana LG; The InspECT Bcc Working Group
Curr Oncol; 2022 Jul; 29(8):5324-5337. PubMed ID: 36005161
[TBL] [Abstract] [Full Text] [Related]
12. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
13. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Plaçais L; Dalle S; Dereure O; Trabelsi S; Dalac S; Legoupil D; Montaudié H; Arnault JP; De Quatrebarbes J; Saiag P; Brunet-Possenti F; Lesimple T; Maubec E; Aubin F; Granel-Brocard F; Grob JJ; Stoebner PE; Allayous C; Oriano B; Dutriaux C; Mortier L; Lebbe C
Ann Rheum Dis; 2022 Oct; 81(10):1445-1452. PubMed ID: 35788496
[TBL] [Abstract] [Full Text] [Related]
14. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract] [Full Text] [Related]
15. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
Franken MG; Leeneman B; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; van der Veldt AAM; Westgeest HM; Wouters MWJM; Haanen JBAG; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100320. PubMed ID: 34856511
[TBL] [Abstract] [Full Text] [Related]
16. Implanted spinal neuromodulation interventions for chronic pain in adults.
O'Connell NE; Ferraro MC; Gibson W; Rice AS; Vase L; Coyle D; Eccleston C
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013756. PubMed ID: 34854473
[TBL] [Abstract] [Full Text] [Related]
17. LIMPRINT in Italy.
Cestari M; Michelini S; Ricci M; Franks PJ; Murray S; Moffatt CJ; Michelini S
Lymphat Res Biol; 2021 Oct; 19(5):468-472. PubMed ID: 34672792
[No Abstract] [Full Text] [Related]
18. Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.
Koelblinger P; Hoellwerth M; Dernoscheg MT; Koch L; Richtig E; Wanner M; Nguyen VA; Ostermann H; Bauer JW; Laimer M
J Dtsch Dermatol Ges; 2021 Aug; 19(8):1186-1198. PubMed ID: 34255435
[TBL] [Abstract] [Full Text] [Related]
19. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
Erickson AW; Habbous S; Wright F; Lofters AK; Jerzak KJ; Das S
JAMA Oncol; 2021 Aug; 7(8):1220-1224. PubMed ID: 34081080
[TBL] [Abstract] [Full Text] [Related]
20. An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway.
Alberti Violetti S; Alaibac M; Ardigò M; Baldo A; DI Meo N; Massone C; Onida F; Simontacchi G; Zalaudek I; Pimpinelli N; Quaglino P; Berti E
Ital J Dermatol Venerol; 2021 Aug; 156(4):413-421. PubMed ID: 34037370
[TBL] [Abstract] [Full Text] [Related]
[Next]
